Moving at the speed of patient need
BridgeBio Pharma is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. Using a decentralized hub-and-spoke model, focused affiliate teams partner with leading academic institutions to accelerate discovery. The company has enrolled 2,000+ patients in clinical trials globally and has conducted 6 Phase 3 trials, with programs targeting 48 unique disease indications.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2025
Jan 2024
Sep 2023
Jan 2021
Jan 2019
Sep 2017
Create a free account to see which investors have funded this company.
Create Free AccountClinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
Biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases
